Humira biosimilars set the stage for long-awaited 2023 US launches
Pharmaceutical Technology
DECEMBER 4, 2022
Starting in January, multiple biosimilars of AbbVie’s blockbuster drug Humira are set to flood the US pharmaceutical market. The arrival of Humira biosimilars is expected to provide cost-effective alternatives to the anti-tumor necrosis factor (TNF) biologic, but their eventual position on the market remains to be seen.
104 
Let's personalize your content